Zacks: Analysts Expect OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per Share
Analysts expect that OncoSec Medical Inc (NASDAQ:ONCS) will announce ($0.23) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoSec Medical’s earnings. OncoSec Medical posted earnings per share of ($0.29) in the same quarter last year, which indicates a positive year-over-year growth rate of 20.7%. The company is scheduled to announce its next quarterly earnings report on Thursday, December 14th.
According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.86) per share for the current financial year. For the next financial year, analysts expect that the firm will report earnings of ($0.71) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for OncoSec Medical.
OncoSec Medical (NASDAQ:ONCS) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05).
OncoSec Medical (ONCS) traded down $0.01 during trading hours on Monday, reaching $1.73. 517,273 shares of the company traded hands, compared to its average volume of 864,304. OncoSec Medical has a 1-year low of $0.88 and a 1-year high of $2.95.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/11/zacks-analysts-expect-oncosec-medical-inc-oncs-will-announce-earnings-of-0-23-per-share.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.